[18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma

Sungeun Kim, June Key Chung, Soon Beom Kang, Moon Hong Kim, Jae Min Jeong, Dong Soo Lee, Myung Chul Lee

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The aim of this study was to compare the prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) with that of second-look laparotomy (SLL) in patients with advanced ovarian carcinoma following primary chemotherapy. Fifty-five patients who had undergone cytoreductive surgery and adjuvant chemotherapy for advanced ovarian carcinoma were enrolled in the study. Thirty patients underwent SLL after primary treatment (SLL group), while 25 underwent FDG PET after primary treatment without SLL (PET group). We retrospectively reviewed the medical records of the 55 patients for comparison of progression-free interval and disease-free interval between the two groups. Ovarian carcinomas recurred in 37 of the 55 patients. When the progression-free interval and the disease-free interval in patients in the PET group were compared with those in the SLL group, no significant differences were observed. The progression-free interval in the PET and SLL groups were 28.8±12.7 months and 30.6±13.7 months, respectively (P=0.29). The disease-free interval in the negative PET group was 40.5±11.6 months, and that in the negative SLL group was 48.6±12. 1 months (P=0.12). In conclusion, FDG PET has a similar prognostic value to SLL, and can substitute for SLL in the follow-up of patients who have had ovarian carcinoma, especially when there is a high risk for recurrence.

Original languageEnglish
Pages (from-to)196-201
Number of pages6
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume31
Issue number2
DOIs
Publication statusPublished - 2004 Feb 1
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Positron-Emission Tomography
Laparotomy
Carcinoma
Adjuvant Chemotherapy
Medical Records
Recurrence
Drug Therapy
Therapeutics

Keywords

  • FDG PET
  • Ovarian carcinoma
  • Second-look laparotomy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

[18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. / Kim, Sungeun; Chung, June Key; Kang, Soon Beom; Kim, Moon Hong; Jeong, Jae Min; Lee, Dong Soo; Lee, Myung Chul.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 31, No. 2, 01.02.2004, p. 196-201.

Research output: Contribution to journalArticle

Kim, Sungeun ; Chung, June Key ; Kang, Soon Beom ; Kim, Moon Hong ; Jeong, Jae Min ; Lee, Dong Soo ; Lee, Myung Chul. / [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. In: European Journal of Nuclear Medicine and Molecular Imaging. 2004 ; Vol. 31, No. 2. pp. 196-201.
@article{6fa92e8401214be5b877b0f2db06bf8d,
title = "[18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma",
abstract = "The aim of this study was to compare the prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) with that of second-look laparotomy (SLL) in patients with advanced ovarian carcinoma following primary chemotherapy. Fifty-five patients who had undergone cytoreductive surgery and adjuvant chemotherapy for advanced ovarian carcinoma were enrolled in the study. Thirty patients underwent SLL after primary treatment (SLL group), while 25 underwent FDG PET after primary treatment without SLL (PET group). We retrospectively reviewed the medical records of the 55 patients for comparison of progression-free interval and disease-free interval between the two groups. Ovarian carcinomas recurred in 37 of the 55 patients. When the progression-free interval and the disease-free interval in patients in the PET group were compared with those in the SLL group, no significant differences were observed. The progression-free interval in the PET and SLL groups were 28.8±12.7 months and 30.6±13.7 months, respectively (P=0.29). The disease-free interval in the negative PET group was 40.5±11.6 months, and that in the negative SLL group was 48.6±12. 1 months (P=0.12). In conclusion, FDG PET has a similar prognostic value to SLL, and can substitute for SLL in the follow-up of patients who have had ovarian carcinoma, especially when there is a high risk for recurrence.",
keywords = "FDG PET, Ovarian carcinoma, Second-look laparotomy",
author = "Sungeun Kim and Chung, {June Key} and Kang, {Soon Beom} and Kim, {Moon Hong} and Jeong, {Jae Min} and Lee, {Dong Soo} and Lee, {Myung Chul}",
year = "2004",
month = "2",
day = "1",
doi = "10.1007/s00259-003-1367-y",
language = "English",
volume = "31",
pages = "196--201",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma

AU - Kim, Sungeun

AU - Chung, June Key

AU - Kang, Soon Beom

AU - Kim, Moon Hong

AU - Jeong, Jae Min

AU - Lee, Dong Soo

AU - Lee, Myung Chul

PY - 2004/2/1

Y1 - 2004/2/1

N2 - The aim of this study was to compare the prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) with that of second-look laparotomy (SLL) in patients with advanced ovarian carcinoma following primary chemotherapy. Fifty-five patients who had undergone cytoreductive surgery and adjuvant chemotherapy for advanced ovarian carcinoma were enrolled in the study. Thirty patients underwent SLL after primary treatment (SLL group), while 25 underwent FDG PET after primary treatment without SLL (PET group). We retrospectively reviewed the medical records of the 55 patients for comparison of progression-free interval and disease-free interval between the two groups. Ovarian carcinomas recurred in 37 of the 55 patients. When the progression-free interval and the disease-free interval in patients in the PET group were compared with those in the SLL group, no significant differences were observed. The progression-free interval in the PET and SLL groups were 28.8±12.7 months and 30.6±13.7 months, respectively (P=0.29). The disease-free interval in the negative PET group was 40.5±11.6 months, and that in the negative SLL group was 48.6±12. 1 months (P=0.12). In conclusion, FDG PET has a similar prognostic value to SLL, and can substitute for SLL in the follow-up of patients who have had ovarian carcinoma, especially when there is a high risk for recurrence.

AB - The aim of this study was to compare the prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) with that of second-look laparotomy (SLL) in patients with advanced ovarian carcinoma following primary chemotherapy. Fifty-five patients who had undergone cytoreductive surgery and adjuvant chemotherapy for advanced ovarian carcinoma were enrolled in the study. Thirty patients underwent SLL after primary treatment (SLL group), while 25 underwent FDG PET after primary treatment without SLL (PET group). We retrospectively reviewed the medical records of the 55 patients for comparison of progression-free interval and disease-free interval between the two groups. Ovarian carcinomas recurred in 37 of the 55 patients. When the progression-free interval and the disease-free interval in patients in the PET group were compared with those in the SLL group, no significant differences were observed. The progression-free interval in the PET and SLL groups were 28.8±12.7 months and 30.6±13.7 months, respectively (P=0.29). The disease-free interval in the negative PET group was 40.5±11.6 months, and that in the negative SLL group was 48.6±12. 1 months (P=0.12). In conclusion, FDG PET has a similar prognostic value to SLL, and can substitute for SLL in the follow-up of patients who have had ovarian carcinoma, especially when there is a high risk for recurrence.

KW - FDG PET

KW - Ovarian carcinoma

KW - Second-look laparotomy

UR - http://www.scopus.com/inward/record.url?scp=0842269090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842269090&partnerID=8YFLogxK

U2 - 10.1007/s00259-003-1367-y

DO - 10.1007/s00259-003-1367-y

M3 - Article

VL - 31

SP - 196

EP - 201

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 2

ER -